Business
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer
Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for pros...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer\nBria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed manufacturing clinical supplies of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer. In August 2025, BriaCell was awarded a $2 million non-dilutive grant from the US National Cancer Institute to support the manufacturing and planned clinical evaluation of Bria-PROS+. “We are pleased to announce the completion of clinical supply manufacturing for Bria-PROS+, our next generation personalized immunotherapy candidate for prostate cancer,” stated Dr. William V. Williams, BriaCell’s President & CEO. “The design of Bria-PROS+ is intended to support enhanced immune system activation while maintaining a favorable safety profile. We look forward to advancing Bria-PROS+ into the clinic as we seek to develop new treatment options for prostate cancer patients who do not respond to available therapies.” As reported in BriaCell’s recent AACR preclinical poster presentation, Bria-PROS+ demonstrated activation of both adaptive and innate immunity including activation of naïve (resting) T-cells, dendritic cells and natural killer (NK) cells. BriaCell believes these preclinical findings support further clinical evaluation as a potential immunotherapy for prostate cancer. Bria-PROS+ is based on the same Bria-OTS+ platform as Bria-BRES+, BriaCell’s next generation breast cancer immunotherapy candidate, which recently received FDA clearance of its Investigational New Drug (IND) application. Bria-PROS+ builds on Bria-Cell’s Bria-OTS clinical program in breast cancer, whe...